Olverembatinib · HQP-1351, D-824

What is Olverembatinib?

Olverembatinib is an orally bioavailable inhibitor of Bcr-Abl, c-Kit, Akt, and ERK kinases. It targets wild-type and mutant Bcr-Abl including the T315I variant. The drug is studied in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

HQP-1351, D-824, GZD-824

Drug type

Small molecule

Targets

BCR-ABL (BCR), c-Kit (KIT), Akt (AKT1), ERK (MAPK1)

Mechanism

Inhibitor of BCR-ABL (BCR), c-Kit (KIT) and Akt (AKT1)

Pathways

MAPK/ERK signaling, PI3K/Akt signaling

Therapy area

Oncology

Developer

Ascentage Pharma Group Inc. (AAPG)

Also in trials of

AMGN

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 3

UNII

KV1M7Q3CBP

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B Cell Precursor Type Acute LeukemiaBlinatumomabChronic Myeloid LeukemiaLeukemia, Lymphoblastic, Acute, Philadelphia-PositiveLeukemia, Myeloid, ChronicLymphoblastic LeukemiaMyeloid LeukemiaOlverembatinibPh+ ALLPharmacokineticPhase II Clinical TrialPhiladelphia Chromosome PositivePhiladelphia Positive Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia, Chronic Phase

Other drugs acting on BCR / KIT / AKT1 / MAPK1

More from Ascentage Pharma Group

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT04126681
• ClinicalTrials.gov NCT04260022
• ClinicalTrials.gov NCT06051409
• ClinicalTrials.gov NCT07282093

Updated Oct 3, 2026. Something wrong or missing? Report it on the AAPG page.